ClinicalTrials.gg
CompletedNCT02686164Updated Aug 28, 2019Results posted

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

A Phase 1 interventional study of Lenvatinib and Midazolam in Tumors, sponsored by Eisai Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, non-randomized Phase 1 study in participants with advanced solid tumors, excluding hepatocellular carcinoma (HCC), that have progressed after treatment with approved therapies, or for which there are no standard therapies available. The study will also include participants with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Its primary intent is to determine the effect of lenvatinib on CYP3A4 activity as well as to assess the safety and activity of lenvatinib in these participants. The study will be conducted in the following 3 phases: Pretreatment Phase, Treatment Phase, and Extension Phase.

02

Conditions studied

  • Tumors

Browse trials for

Keywords

  • Lenvatinib
  • Lenvima
  • E7080
  • Phase 1
  • Solid tumors
  • Midazolam
  • CYP3A4
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 51 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater than or equal to 18 years at the time of .
  2. or cytologically confirmed advanced solid tumors (excluding HCC) that have progressed following standard therapy, or for which no standard therapy exists (including surgery or radiation therapy) or participants with RR-DTC.
  3. (ECOG) performance status of 0 to 1.
  4. greater than or equal to 3 months.
  5. Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal to 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Cycle 1 Day 1.
  6. Adequate renal function defined as calculated greater than or equal to 30 mL/min per the Cockcroft and Gault formula.
  7. Adequate bone marrow function:

    1. (ANC) greater than or equal to 750/mm3 (greater than or equal to 0.75 X 10\^9/L)
    2. greater than or equal to 75,000/mm3 (greater than or equal to 75 X 10\^9/L)
    3. greater than or equal to 9.0 g/dL
  8. Adequate blood coagulation function as evidenced by an (INR) less than or equal to 1.5.
  9. Adequate liver function:

    1. Total less than or equal to 1.5 X the (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome
    2. Alkaline phosphatase (ALP), (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (less than or equal to 5 X ULN if participant has liver ). If ALP is greater than 3 X ULN (in the absence of liver metastases) or greater than 5 X ULN (in the presence of liver metastases) AND the participant also is known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of total ALP.
  10. Participants with or C are eligible on the condition that they have adequate liver function as defined by Inclusion Criterion 9.
  11. All prior therapy related toxicities must have resolved to Grade less than 2 severity per (CTCAE version 4.03), except alopecia and infertility.
  12. (LVEF) greater than 50% on echocardiography or multiple gated acquisition (MUGA) scan.
  13. Females must not be lactating or pregnant at screening or baseline (as documented by a negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of 25 IU/L or equivalent units of B-hCG). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  14. Participant must voluntarily agree to provide written informed consent.
  15. Participant must be willing and able to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participants with diagnosis of HCC.
  2. Participants with anaplastic thyroid carcinoma with major blood vessel invasion or infiltration.
  3. Participants having greater than (>) 1 plus (+) proteinuria on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with urine protein greater than or equal to (>=1) gram per 24 hours will be ineligible.
  4. Participants with known or untreated . Participants with known brain metastases will be eligible if they have completed the primary brain therapy (such as whole brain radiotherapy, stereotactic radiosurgery, or complete surgical resection) and if they have remained clinically stable, asymptomatic, and off for at least 28 days.
  5. Participants taking medications that are known potent inducers/inhibitors or substrates with narrow therapeutic indices or St. John's Wort.
  6. Participants unwilling to exclude grapefruit juice and grapefruit from their diet.
  7. Participants who have received any anticancer treatment within 3 weeks or any agent within 30 days before the first dose of study drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.
  8. Major surgery within 4 weeks before the first dose of study drug.
  9. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the bioavailability of lenvatinib or midazolam.
  10. Significant cardiovascular impairment: history of congestive heart failure greater than (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment (including oral anticoagulation).
  11. A (ECG) abnormality (ie, interval [QTc] interval greater than 480 msec when electrolyte balance is normal), or a history of risk factors for torsade de pointes, hypokalemia, long QT syndrome, or the use of concomitant medications resulting in a prolongation of QTc interval.
  12. Active hemoptysis (bright red blood of at least 2.5 mL ie, half teaspoon) within 3 weeks prior to the first dose of study drug.
  13. Active infection (any infection requiring treatment).
  14. Known to any component of lenvatinib or midazolam.
  15. Prior treatment with lenvatinib.
  16. Achlorhydria or use of antacids, proton-pump inhibitors, or other drugs known to raise gastric pH within 2 weeks before study drug administration.
  17. participants, including participants known to be infected with (HIV).
  18. Any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the participant's participation in this study.
  19. Participants who meet any of the following criteria will be excluded from this study:

Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 international units per liter (IU/L) or equivalent units of ß-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.

OR Females of who do not agree to use a highly effective method of for the entire study period and for 28 days after study drug discontinuation i.e. i) total abstinence (if it is their preferred and usual lifestyle) ii) an intrauterine device (IUD) or hormone releasing system (IUS) iii) a contraceptive implant iv. an oral contraceptive (with additional barrier method) OR who do not have a vasectomized partner with confirmed azoospermia. For sites outside of the European Union (EU), it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the participant, then the participant must agree to use a medically acceptable method of contraception, i.e. double barrier methods of contraception such as condom plus diaphragm or cervical/vault cap with spermicide. All females will be considered to be of childbearing potential unless they are [amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause] or have been sterilized surgically [i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]

Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Lenvatinib + midazolam

    Participants with histologically confirmed unresectable or refractory solid tumors.

    Drug: Lenvatinib · Drug: Midazolam

Interventions

  • Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.

    Also known as: Lenvima, E7080

  • DrugMidazolam

    Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.

06

What researchers measure

Primary outcomes

  1. AUC(0-24): Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose for Midazolam and 1'-Hydroxymidazolam

    Time frame: Cycle 1 Day-3: 0-24 hours; Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 14: 0-24 hours (Duration of each cycle=28 days)

  2. Cmax: Maximum Observed Plasma Concentration for Midazolam and 1'-Hydroxymidazolam

    Time frame: Cycle 1 Day-3: 0-24 hours; Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 14: 0-24 hours (Duration of each cycle=28 days)

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: First dose of study drug (Baseline) up to 28 days after last dose of study drug or until resolution, whichever came first (up to approximately 2.5 years)

07

Results

Posted Aug 28, 2019

Participant flow

Participants took part in the study at 4 investigative sites in the United States from 18 Apr 2016 to 16 Aug 2018.

Participant flow — Overall Study
MilestoneMidazolam + Lenvatinib
Started30
Completed27
Not completed3
Withdrew: Adverse event1
Withdrew: Withdrawal of consent1
Withdrew: Clinical progression1

Outcome measures

PrimaryAUC(0-24): Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose for Midazolam and 1'-Hydroxymidazolam
Time frame:
Cycle 1 Day-3: 0-24 hours; Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 14: 0-24 hours (Duration of each cycle=28 days)
Reported as:
Mean · hour*nanograms per milliliter (h*ng/mL)
AUC(0-24): Area Under the Concentration-time Curve From Time Zero to 24 Hours Postdose for Midazolam and 1'-Hydroxymidazolam
hour*nanograms per milliliter (h*ng/mL)Cycle 1 Day -3: MidazolamCycle 1 Day 1: Lenvatinib + MidazolamCycle 1 Day 14: Lenvatinib + Midazolam
Midazolam92.5 ± 34.589.7 ± 42.0117 ± 61.1
1'-hydroxymidazolam38.5 ± 26.548.6 ± 47.841.3 ± 34.3
Statistical analysis
  • Cycle 1 Day -3: Midazolam vs Cycle 1 Day 1: Lenvatinib + Midazolam · Geometric mean ratio: 0.914 · 90% CI 0.850 to 0.983
  • Cycle 1 Day -3: Midazolam vs Cycle 1 Day 14: Lenvatinib + Midazolam · Geometric mean ratio: 1.148 · 90% CI 0.938 to 1.404
  • Cycle 1 Day -3: Midazolam vs Cycle 1 Day 1: Lenvatinib + Midazolam · Geometric mean ratio: 1.120 · 90% CI 0.940 to 1.335
  • Cycle 1 Day -3: Midazolam vs Cycle 1 Day 14: Lenvatinib + Midazolam · Geometric mean ratio: 1.199 · 90% CI 1.057 to 1.360
PrimaryCmax: Maximum Observed Plasma Concentration for Midazolam and 1'-Hydroxymidazolam
Time frame:
Cycle 1 Day-3: 0-24 hours; Cycle 1 Day 1: 0-24 hours; Cycle 1 Day 14: 0-24 hours (Duration of each cycle=28 days)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for Midazolam and 1'-Hydroxymidazolam
nanogram per milliliter (ng/mL)Cycle 1 Day -3: MidazolamCycle 1 Day 1: Lenvatinib + MidazolamCycle 1 Day 14: Lenvatinib + Midazolam
Midazolam26.5 ± 10.724.8 ± 17.428.3 ± 13.9
1'-hydroxy midazolam11.0 ± 8.6412.7 ± 11.610.7 ± 11.6
Statistical analysis
  • Cycle 1 Day -3: Midazolam vs Cycle 1 Day 1: Lenvatinib + Midazolam · Geometric mean ratio: 0.862 · 90% CI 0.753 to 0.988
  • Cycle 1 Day -3: Midazolam vs Cycle 1 Day 14: Lenvatinib + Midazolam · Geometric mean ratio: 1.027 · 90% CI 0.852 to 1.238
  • Cycle 1 Day -3: Midazolam vs Cycle 1 Day 1: Lenvatinib + Midazolam · Geometric mean ratio: 1.055 · 90% CI 0.879 to 1.268
  • Cycle 1 Day -3: Midazolam vs Cycle 1 Day 14: Lenvatinib + Midazolam · Geometric mean ratio: 0.940 · 90% CI 0.845 to 1.046
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
First dose of study drug (Baseline) up to 28 days after last dose of study drug or until resolution, whichever came first (up to approximately 2.5 years)
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsMidazolam + Lenvatinib
TEAEs30
SAEs10

Adverse events

Collected over First dose of study drug (Baseline) up to 28 days after last dose of study drug or until resolution, whichever came first (up to approximately 2.5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Midazolam + Lenvatinib1/30 (3.3%)10/30 (33.3%)28/30 (93.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventMidazolam + Lenvatinib
HypertensionVascular disorders3/30
Abdominal painGastrointestinal disorders2/30
BradycardiaCardiac disorders1/30
Stress cardiomyopathyCardiac disorders1/30
Abdominal pain upperGastrointestinal disorders1/30
Intestinal obstructionGastrointestinal disorders1/30
Rectal haemorrhageGastrointestinal disorders1/30
AstheniaGeneral disorders1/30
PyrexiaGeneral disorders1/30
Cerebral haemorrhageNervous system disorders1/30
Most frequent other events
Showing 10 of 22
Most frequent other events
EventMidazolam + Lenvatinib
FatigueGeneral disorders13/30
DiarrhoeaGastrointestinal disorders10/30
NauseaGastrointestinal disorders10/30
HypothyroidismEndocrine disorders9/30
VomitingGastrointestinal disorders7/30
Decreased appetiteMetabolism and nutrition disorders7/30
ConstipationGastrointestinal disorders5/30
AstheniaGeneral disorders5/30
ThrombocytopeniaBlood and lymphatic system disorders4/30
Abdominal painGastrointestinal disorders4/30

Baseline characteristics

Safety analysis set included participants who received at least 1 dose of midazolam or lenvatinib and had at least 1 postdose safety assessment.

Age, Continuous
Age, Continuous(years)Midazolam + Lenvatinib
Mean59.4 ± 12.66
Sex: Female, Male
Sex: Female, Male(Participants)Midazolam + Lenvatinib
Female15
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Midazolam + Lenvatinib
Hispanic or Latino6
Not Hispanic or Latino24
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Midazolam + Lenvatinib
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American5
White19
More than one race0
Unknown or Not Reported5
08

Study locations

4 sites
  • Facility # 1
    Detroit, Michigan, United States
  • Facility # 1
    Bronx, New York, United States
  • Facility # 1
    Philadelphia, Pennsylvania, United States
  • Facility # 1
    San Antonio, Texas, United States
09

References and documents

Publications

  • Shumaker R, Ren M, Aluri J, Dutcus CE, Rance C, He C. An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors. Eur J Drug Metab Pharmacokinet. 2020 Jun;45(3):373-383. doi: 10.1007/s13318-020-00607-7. PubMed 32067158 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Jan 2017, 8 months.

Results were first posted in Aug 2019, 2 years 7 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 8 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2016
First posted
Feb 19, 2016
StartActual
Apr 18, 2016
Primary completionActual
Jan 4, 2017
CompletionActual
Aug 16, 2018
Results first posted
Aug 28, 2019
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02686164
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Feb 19, 2016
Start date
Apr 18, 2016
Primary completion
Jan 4, 2017
Completion
Aug 16, 2018
Results posted
Aug 28, 2019
Last update
Aug 28, 2019

Oversight

FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion